^
    1d
    A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=138, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Nov 2028 --> May 2028 | Trial primary completion date: Jan 2028 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • luxdegalutamide (ARV-766)
    1d
    Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=52, Recruiting, Weill Medical College of Cornell University | Active, not recruiting --> Recruiting | N=37 --> 52
    Enrollment open • Enrollment change
    |
    CELLSEARCH®
    |
    Keytruda (pembrolizumab) • Xtandi (enzalutamide) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    6d
    177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia (clinicaltrials.gov)
    P2, N=40, Suspended, M.D. Anderson Cancer Center | Initiation date: Dec 2025 --> Aug 2025 | Recruiting --> Suspended
    Trial initiation date • Trial suspension
    |
    FOLH1 positive
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    14d
    AlphaBreak: FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=110, Active, not recruiting, Fusion Pharmaceuticals Inc. | Trial primary completion date: Jul 2026 --> Dec 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation • FOLH1 positive
    |
    FPI-2265
    14d
    177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer (clinicaltrials.gov)
    P2, N=55, Active, not recruiting, Weill Medical College of Cornell University | Trial completion date: May 2026 --> Sep 2026
    Trial completion date
    |
    177Lu-rosopatamab tetraxetan (TLX591)
    14d
    LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=37, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting | Trial completion date: Jul 2026 --> Mar 2027 | Trial primary completion date: Jul 2026 --> Oct 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    carboplatin • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    14d
    ARREST: External Beam and Radioligand Radiotherapy for mCRPC (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Centre hospitalier de l'Université de Montréal (CHUM) | Initiation date: Jan 2026 --> May 2026
    Trial initiation date
    |
    lutetium zadavotide guraxetan (PNT2002)
    14d
    A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=134, Active, not recruiting, Novartis Pharmaceuticals
    Trial initiation date
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • luxdegalutamide (ARV-766)
    15d
    ARTISAN: Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P1, N=80, Active, not recruiting, ARTBIO Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    AB001
    15d
    A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Oct 2026 --> Oct 2027 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    18d
    FAERS based pharmacovigilance study and network pharmacology analysis of Lutathera and Pluvicto. (PubMed, Appl Radiat Isot)
    This FAERS analysis characterizes agent-specific safety profiles, informing pharmacovigilance strategies. Mechanistic profiling of adverse drug reactions optimizes evidence-based treatment, enhancing medication safety and refining benefit-risk profiles in clinical practice.
    Journal • Adverse events
    |
    ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • SSTR (Somatostatin Receptor)
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Lutathera (lutetium Lu 177 dotatate)
    19d
    Radiolabeled cyclic peptides in precision oncology: Current advances and future perspectives. (PubMed, J Control Release)
    In recent years, the regulatory approval of radiopharmaceuticals such as [177Lu]Lu-DOTATATE and [177Lu]Lu-PSMA-617, alongside their diagnostic counterparts [68Ga]Ga-DOTATATE and [68Ga]Ga-PSMA-11, has propelled theranostics into the clinical mainstream, marking a transformative shift in nuclear medicine and precision oncology...With their molecular precision, structural versatility, and therapeutic adaptability, cyclic peptides are positioned at the forefront of next-generation radiopharmaceutical development. As the field continues to evolve toward increasingly personalized and molecularly targeted cancer therapies, radiolabeled cyclic peptides are poised to play a pivotal role in redefining the future landscape of radiotherapy.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    SSTR (Somatostatin Receptor)
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)